Gemzar is a medicine containing the active ingredient(s) gemcitabine. On this page you will find out more about Gemzar, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: gemcitabine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Gemzar 200 mg powder for injection, 1 vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
For treatment of patients with locally advanced or metastatic non-small cell lung cancer. For treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas; and for patients with 5-FU refractory pancreatic cancer. Alone or in combination with cisplatin for the treatment of patients with bladder cancer. Gemzar, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent, or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contra-indicated. Gemzar, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
Table of characteristics
|Visual appearance||White to off-white plug or powder|
|Dosage Form||Injection, powder for|
|Route of administration||Intravenous|
1 x 200mg (in 10mL vial): Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||No information available|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.